Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai to present new epilepsy drug data at AES 2017

Eisai to present new epilepsy drug data at AES 2017

28th November 2017

Eisai has announced that it will be attending the upcoming American Epilepsy Society (AES) annual meeting, where it will share its latest epilepsy research insights.

During the meeting in Washington, DC from December 1st to 5th, the company will share insights into the performance of key antiepileptic drugs such as Fycompa (perampanel) and Inovelon (rufinamide).

For Fycompa, this will include a report on the extrapolation of data from phase III clinical studies assessing the benefits of adjunctive treatment with the drug, which will help demonstrate its benefits as a monotherapy for partial seizures.

Inovelon, meanwhile, will be the subject of a poster presentation highlighting its long-term safety and efficacy among patients with Lennox-Gastaut syndrome in a real-world setting in Japan. In total, Eisai will share nine poster presentations at this year's AES meeting.

The company said: "Eisai considers neurology a therapeutic area of focus, and strives to maximise the value of perampanel and rufinamide to further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.